Vascular Disease in Scleroderma: Angiogenesis and Vascular Repair

Rheumatic Disease Clinics of North America

Volumn 34, Issue 1, 2008, Pages 73-79

  Mulligan Kehoe, Mary Jo ^a,b   Simons, Michael ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL INJURY; BONE MARROW; BONE MARROW CELL; CELL MOTILITY; DISEASE COURSE; ENDOTHELIUM CELL; FIBROSIS; HEMOSTASIS; HOMEOSTASIS; HUMAN; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGENERATION; REVIEW; SCLERODERMA; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULARIZATION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; CAPILLARIES; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES; WOUND HEALING;

EID: 40349085655     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.12.006     Document Type: Review

References (52)

1. Eming S.A., and Krieg T. Molecular mechanisms of VEGF-A action during tissue repair. J Investig Dermatol Symp Proc 11 1 (2006) 79-86
2. Davies C.A., Jeziorska M., Freemont A.J., et al. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37 2 (2006) 190-197
3. Higley H., Persichitte K., Chu S., et al. Immunocytochemical localization and serologic detection of transforming growth factor beta 1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 37 2 (1994) 278-288
4. Mackiewicz Z., Sukura A., Povilenaite D., et al. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol 20 5 (2002) 641-646
5. Mulligan-Kehoe M.J., and Simons M. Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 9 2 (2007) 173-179
6. Burger R.A. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25 20 (2007) 2902-2908
7. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 31 (2005) 8033-8040
8. Gill M., Dias S., Hattori K., et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 88 2 (2001) 167-174
9. Kuwana M., Okazaki Y., Yasuoka H., et al. Defective vasculogenesis in systemic sclerosis. Lancet 364 9434 (2004) 603-610
10. Del Papa N., Quirici N., Soligo D., et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54 8 (2006) 2605-2615
11. Cipriani P., Guiducci S., Miniati I., et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56 6 (2007) 1994-2004
12. Cutolo M., Pizzorni C., and Sulli A. Nailfold video-capillaroscopy in systemic sclerosis. Z Rheumatol 63 6 (2004) 457-462
13. Distler O., Distler J.H., Scheid A., et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95 1 (2004) 109-116
14. Simons M. Angiogenesis: where do we stand now?. Circulation 111 12 (2005) 1556-1566
15. Simons M., and Ware J.A. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2 11 (2003) 863-871
16. Lu H., Dhanabel M., Volk R., et al. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun 258 3 (1999) 668-673
17. Staton C.A., and Lewis C.E. Angiogenesis inhibitors found within the haemostasis pathway. J Cell Mol Med 9 2 (2005) 286-302
18. Wigley F.M., and Flavahan N.A. Raynaud's phenomenon. Rheum Dis Clin North Am 22 4 (1996) 765-781
19. Giusti B., Serrati S., Margheri F., et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 52 11 (2005) 3618-3628
20. Bhoola K.D., Figueroa C.D., and Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44 1 (1992) 1-80
21. Schmaier A.H., and McCrae K.R. The plasma kallikrein/kinin systems: its evolution from contact activation. J Thromb Haemost 5 (2007) 2323-2329
22. Plendl J., Snyman C., Naidoo S., et al. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem 381 11 (2000) 1103-1115
23. Emanueli C., and Madeddu P. Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol Sci 22 9 (2001) 478-484
24. Del Rosso A., Distler O., Milia A.F., et al. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis 64 3 (2005) 382-387
25. Giusti B., Fibbi G., Margheri F., et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 8 4 (2006) R115
26. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21 7 (2001) 1104-1117
27. Cao Y., Ji R.W., Davidson D., et al. Kringle domains of human angiostatin: characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 271 46 (1996) 29461-29467
28. Keck R.G., Berleau L., Harris R., et al. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. Arch Biochem Biophys 344 1 (1997) 103-113
29. Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp (Warsz) 50 5 (2002) 325-331
30. Jinnin M., Ihn H., Mimura Y., et al. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol 124 2 (2005) 324-330
31. Lijnen H.R., Ugwu F., Bini A., et al. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37 14 (1998) 4699-4702
32. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., et al. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274 41 (1999) 29568-29571
33. Patterson B.C., and Sang Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272 46 (1997) 28823-28825
34. Stathakis P., Fitzgerald M., Matthias L.J., et al. Generation of angiostatin by reduction and proteolysis of plasmin: catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 272 33 (1997) 20641-20645
35. Mulligan-Kehoe M.J., Drinane M.C., Mollmark J., et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 56 10 (2007) 3448-3458
36. Weihrauch D., Xu H., Shi Y., et al. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol 293 3 (2007) H1432-H1441
37. Dziankowska-Bartkowiak B., Waszczykowska E., Dziankowska-Zaboroszczyk E., et al. Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis: association with pulmonary involvement. Clin Exp Rheumatol 24 5 (2006) 508-513
38. Vassalli J.D., Baccino D., and Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100 1 (1985) 86-92
39. Wei Y., Waltz D.A., Rao N., et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269 51 (1994) 32380-32388
40. D'Alessio S., Fibbi G., Cinelli M., et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50 10 (2004) 3275-3285
41. Margheri F., Manetti M., Serrati S., et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 54 12 (2006) 3926-3938
42. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285 5435 (1999) 1926-1928
43. Staton C.A., Brown N.J., Rodgers G.R., et al. Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 103 2 (2004) 601-606
44. Colorado P.C., Torre A., Kamphaus G., et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60 9 (2000) 2520-2526
45. Kamphaus G.D., Colorado P.C., Panka D.J., et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275 2 (2000) 1209-1215
46. Beecken W.D., Engl T., Ringel E.M., et al. An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: clipped beta2-glycoprotein-I. Ann Surg Oncol 13 9 (2006) 1241-1251
47. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 2 (1997) 277-285
48. Ferrara N., Clapp C., and Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129 2 (1991) 896-900
49. Mulligan-Kehoe M.J., Wagner R., Wieland C., et al. A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product. J Biol Chem 276 11 (2001) 8588-8596
50. Kim J.S., Chang J.H., Yu H.K., et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 278 31 (2003) 29000-29008
51. Tolsma S.S., Volpert O.V., Good D.J., et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122 2 (1993) 497-511
52. Stetler-Stevenson W.G., and Seo D.W. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 11 3 (2005) 97-103